Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies.

Chest - 1 Apr 2017

Chee Jonathan, Robinson Bruce W S, Holt Robert A, Creaney Jenette

Abstract excerpt

Harnessing the immune system to fight cancer is an exciting advancement in lung cancer therapy. Antitumor immunity can be augmented by checkpoint blockade therapy, which removes the inhibition/brakes imposed on the immune system by the tumor. Checkpoint blockade therapy with anti-programmed cell death protein 1 (anti-PD-1)/anti-programmed death ligand 1 (anti-PDL-1) antibodies causes tumor regression in about...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cancer Vaccines
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Translational Research, Biomedical

Source

Identifiers

PMID: 27769776
DOI: 10.1016/j.chest.2016.10.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies.PMID 27769776Read ↗

Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.Semantic proximity Read ↗

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Semantic proximity Read ↗

Next-Generation Sequencing of Lung Cancers: Lessons Learned and Future Directions.Semantic proximity Read ↗

Targeted Therapy and Immunotherapy for Lung Cancer.Semantic proximity Read ↗

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.Semantic proximity Read ↗

Current status of molecular diagnostics for lung cancerSemantic proximity Read ↗

Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.Semantic proximity Read ↗

Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?Semantic proximity Read ↗

Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective.Semantic proximity Read ↗

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.Semantic proximity Read ↗

Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.Semantic proximity Read ↗

Pathways to Precision: Guideline for Programmed Death Ligand-1 and Tumor Mutation Burden Testing to Support the Selection of Immune Checkpoint Therapies in Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.